Boronophenylalanine‐Containing Polydopamine Nanoparticles for Enhanced Combined Boron Neutron Capture Therapy and Photothermal Therapy for Melanoma Treatment

Melanoma, the most aggressive skin cancer type, is challenging to treat due to its high metastatic potential and low response to conventional therapies. Innovative approaches, including combination therapies, are crucial for enhancing treatment efficacy while minimizing side effects. It is developed...

Full description

Saved in:
Bibliographic Details
Published in:Advanced functional materials 2024-09, Vol.34 (38), p.n/a
Main Authors: Dai, Liqun, Wang, Tao, Zhou, Siming, Pan, Lili, Lu, Yi, Yang, Tingyu, Wang, Wentao, Qian, Zhiyong
Format: Article
Language:English
Subjects:
Amino acids
Biocompatibility
Boron
boron neutron capture therapy
boronophenylalanine delivery
BPA‐containing polydopamine
Cell death
melanoma
Nanoparticles
Nuclear capture
Phenylalanine
photothermal therapy
Physiological effects
Side effects
Therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma, the most aggressive skin cancer type, is challenging to treat due to its high metastatic potential and low response to conventional therapies. Innovative approaches, including combination therapies, are crucial for enhancing treatment efficacy while minimizing side effects. It is developed boronophenylalanine‐containing polydopaine (B‐PDA) nanoparticles by encapsulating boronophenylalanine in polydopamine through nitrogen‐boronate coordination, targeting both boron neutron capture therapy (BNCT) and photothermal therapy (PTT). With stability and biocompatibility under physiological conditions, these nanoparticles utilize the phenylalanine residues in BPA to target the overexpressed neutral amino acid transporter 1 (LAT1) in melanoma cells, resulting in enhanced cell‐specific targeting. B‐PDA nanoparticles demonstrated significant photothermal effects under external stimulation, inducing localized heating and triggering heterogeneous tumor cell death, thereby enhancing sensitivity to BNCT. Combining BNCT and PTT, the B‐PDA nanoparticles offer a promising strategy for melanoma treatment. Boronophenylalanine‐containing polydopaine (B‐PDA) nanoparticles, synthesized through the encapsulation of boronophenylalanine in polydopamine, integrate boron neutron capture therapy (BNCT) with photothermal therapy (PTT) for melanoma. Targeting the overexpressed neutral amino acid transporter 1 (LAT1) in melanoma cells, they induce localized heating and enhance sensitivity to BNCT, offering a promising strategy for melanoma treatment.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.202402893